ClinicalTrials.gov

History of Changes for Study: NCT05412173
Pharmacokinetics and Bioequivalence of Molnupiravir, 200 mg Capsules and Lagevrio, 200 mg Capsules in Healthy Volunteers
Latest version (submitted June 6, 2022) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 June 6, 2022 None (earliest Version on record)
Comparison Format:

Scroll up to access the controls

Study NCT05412173
Submitted Date:  June 6, 2022 (v1)

Open or close this module Study Identification
Unique Protocol ID: MOL-05-02-2021
Brief Title: Pharmacokinetics and Bioequivalence of Molnupiravir, 200 mg Capsules and Lagevrio, 200 mg Capsules in Healthy Volunteers
Official Title: A Randomized, Open-label, Cross-over Adaptive Study of the Comparative Pharmacokinetics and Bioequivalence of the Drugs Molnupiravir, Capsules, 200 mg and Lagevrio, Capsules, 200 mg in Healthy Volunteers at Fasted Conditions
Secondary IDs:
Open or close this module Study Status
Record Verification: June 2022
Overall Status: Recruiting
Study Start: April 1, 2022
Primary Completion: December 31, 2023 [Anticipated]
Study Completion: December 31, 2023 [Anticipated]
First Submitted: June 6, 2022
First Submitted that
Met QC Criteria:
June 6, 2022
First Posted: June 9, 2022 [Actual]
Last Update Submitted that
Met QC Criteria:
June 6, 2022
Last Update Posted: June 9, 2022 [Actual]
Open or close this module Sponsor/Collaborators
Sponsor: Valenta Pharm JSC
Responsible Party: Sponsor
Collaborators:
Open or close this module Oversight
U.S. FDA-regulated Drug: No
U.S. FDA-regulated Device: No
Data Monitoring: No
Open or close this module Study Description
Brief Summary:

The study aimed for:

  1. Comparative evaluation of the safety of the drug Molnupiravir, capsules, 200 mg (JSC "Valenta Pharm", Russia), and Lagevrio, capsules, 200 mg (Merck Sharp & Dohme (UK) Limited, UK), based on the analysis of adverse events (AEs);
  2. Comparative assessment of pharmacokinetic parameters and bioequivalence of the drug Molnupiravir, capsules, 200 mg (Valenta Pharm JSC, Russia), and Lagevrio, capsules, 200 mg (Merck Sharp & Dohme (UK) Limited, UK), in healthy volunteers in fasted conditions.
Detailed Description:
Open or close this module Conditions
Conditions: Viral Infection
COVID-19
Keywords:
Open or close this module Study Design
Study Type: Interventional
Primary Purpose: Other
Study Phase: Not Applicable
Interventional Study Model: Crossover Assignment
Number of Arms: 2
Masking: None (Open Label)
Allocation: Randomized
Enrollment: 50 [Anticipated]
Open or close this module Arms and Interventions
Arms Assigned Interventions
RT-sequence
The volunteers will take 1 capsule (200 mg) of Lagevrio (R), 200 mg capsules (Merck Sharp & Dohme (UK) Limited, UK) in Period 1, and 1 capsule (200 mg) of Molnupiravir (T), 200 mg capsules (Valenta Pharm, Russia) in Period 2.
Drug: Molnupiravir
A single dose of R or T drug in each of 2 periods of the study in fasted conditions
TR-sequence
The volunteers will take 1 capsule (200 mg) of the drug Molnupiravir (T), capsules, 200 mg (Valenta Pharm JSC, Russia) in Period 1, and 1 capsule (200 mg) of the drug Lagevrio (R), capsules, 200 mg (Merck Sharp & Dohme (UK) Limited, UK) in Period 2.
Drug: Molnupiravir
A single dose of R or T drug in each of 2 periods of the study in fasted conditions
Open or close this module Outcome Measures
Primary Outcome Measures:
1. Pharmacokinetics - Cmax
[ Time Frame: From 0 to 24 hours (Day 1-2 and Day 8-9) ]

Maximum plasma concentration (Cmax) of β-D-N-4-hydroxycytidine (NHC)
2. Pharmacokinetics - tmax
[ Time Frame: From 0 to 24 hours (Day 1-2 and Day 8-9) ]

Time to reach Cmax (tmax) of NHC
3. Pharmacokinetics - AUC0-t
[ Time Frame: From 0 to 24 hours (Day 1-2 and Day 8-9) ]

Area under the plasma concentration-time curve from time 0 to t (AUC0-t) of NHC
4. Pharmacokinetics - AUC0-inf
[ Time Frame: From 0 to 24 hours (Day 1-2 and Day 8-9) ]

Area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf) of NHC
5. Pharmacokinetics - AUCextr
[ Time Frame: From 0 to 24 hours (Day 1-2 and Day 8-9) ]

Extrapolated AUC of NHC, defined as (AUC0-inf - AUC0-t)/AUC0-inf
6. Pharmacokinetics - t1/2
[ Time Frame: From 0 to 24 hours (Day 1-2 and Day 8-9) ]

Elimination half-life (t1/2) of NHC
7. Pharmacokinetics - kel
[ Time Frame: From 0 to 24 hours (Day 1-2 and Day 8-9) ]

Elimination constant (kel) of NHC
8. Pharmacokinetics - MRT
[ Time Frame: From 0 to 24 hours (Day 1-2 and Day 8-9) ]

Mean residence time (MRT) of NHC
9. Bioequivalence - ratio of Cmax
[ Time Frame: From 0 to 24 hours (Day 1-2 and Day 8-9) ]

Ratio of geometric mean Cmax for NHC after intake of R or T (with 90% confidence intervals)
10. Bioequivalence - ratio of AUC0-t
[ Time Frame: From 0 to 24 hours (Day 1-2 and Day 8-9) ]

Ratio of geometric mean AUC0-t for NHC after intake of R or T (with 90% confidence intervals)
11. Bioequivalence - ratio of AUC0-inf
[ Time Frame: From 0 to 24 hours (Day 1-2 and Day 8-9) ]

Ratio of geometric mean AUC0-inf for NHC after intake of R or T (with 90% confidence intervals)
Secondary Outcome Measures:
1. Safety and Tolerability: adverse event (AE) number and frequency
[ Time Frame: From the screening (and signing informed consent form) to Day 14 of the study or to an early termination visit within the time frame of the study (from Day 0 to Day 14) ]

Number and frequency of adverse events (AEs) or serious AEs (SAEs)
2. Safety and Tolerability: adverse event (AE) characteristics
[ Time Frame: From the screening (and signing informed consent form) to Day 14 of the study or to an early termination visit within the time frame of the study (from Day 0 to Day 14) ]

Description and severity of AEs or serious AEs (SAEs), concomitant therapy for AEs/SAEs, causal relationship, outcomes.
3. Safety and Tolerability: vital signs - systolic blood pressure (SBP)
[ Time Frame: Screening, from Day 0 to Day 2, from Day 7 to Day 9, and/or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

SBP, mmHg
4. Safety and Tolerability: vital signs - diastolic blood pressure (DBP)
[ Time Frame: Screening, from Day 0 to Day 2, from Day 7 to Day 9, and/or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

DBP, mmHg
5. Safety and Tolerability: vital signs - respiratory rate (RR)
[ Time Frame: Screening, from Day 0 to Day 2, from Day 7 to Day 9, and/or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

RR, breaths per minute
6. Safety and Tolerability: vital signs - heart rate (HR)
[ Time Frame: Screening, from Day 0 to Day 2, from Day 7 to Day 9, and/or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

HR, beats per minute
7. Safety and Tolerability: vital signs - body temperature
[ Time Frame: Screening, from Day 0 to Day 2, from Day 7 to Day 9, and/or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

Body temperature, centigrade scale
8. Safety and Tolerability: physical examination results
[ Time Frame: Screening, from Day 0 to Day 2, from Day 7 to Day 9, and/or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

Physical examination results
9. Safety and Tolerability: urinalysis - color
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

Color of the urine
10. Safety and Tolerability: urinalysis - transparency
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

Transparency of the urine
11. Safety and Tolerability: urinalysis - pH
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

pH of the urine
12. Safety and Tolerability: urinalysis - specific gravity
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

Specific gravity of the urine
13. Safety and Tolerability: urinalysis - nitrites
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

Nitrites in the urine (+/-)
14. Safety and Tolerability: urinalysis - protein
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

Protein in the urine (g/L)
15. Safety and Tolerability: urinalysis - glucose
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

Glucose in the urine (mmol/L)
16. Safety and Tolerability: urinalysis - ketones
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

Ketones in the urine (mmol/L)
17. Safety and Tolerability: urinalysis - urobilinogen
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

Urobilinogen in the urine (mmol/L)
18. Safety and Tolerability: urinalysis - bilirubin
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

Bilirubin in the urine (+/-)
19. Safety and Tolerability: urinalysis (microscopy) - red blood cells
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

Red blood cells in the urine (number in sight)
20. Safety and Tolerability: urinalysis (microscopy) - white blood cells
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

White blood cells in the urine (number in sight)
21. Safety and Tolerability: urinalysis (microscopy) - cylinders (except hyaline)
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

Cylinders (except hyaline) in the urine (number in sight)
22. Safety and Tolerability: urinalysis (microscopy) - bacteria
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

Bacteria in the urine (number in sight)
23. Safety and Tolerability: complete blood count - hemoglobin
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

Hemoglobin, g/dL
24. Safety and Tolerability: complete blood count - red blood cells
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

Red blood cells, 10^6/uL
25. Safety and Tolerability: complete blood count - hematocrit
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

Hematocrit, %
26. Safety and Tolerability: complete blood count - platelets
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

Platelets, 10^3/uL
27. Safety and Tolerability: complete blood count - white blood cells
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

White blood cells, 10^3/uL
28. Safety and Tolerability: complete blood count - erythrocyte sedimentation rate
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

Erythrocyte sedimentation rate, mm per hour
29. Safety and Tolerability: complete blood count - neutrophils
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

Neutrophils, %
30. Safety and Tolerability: complete blood count - lymphocytes
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

Lymphocytes, %
31. Safety and Tolerability: complete blood count - eosinophils
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

Eosinophils, %
32. Safety and Tolerability: complete blood count - monocytes
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

Monocytes, %
33. Safety and Tolerability: complete blood count - basophils
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

Basophils, %
34. Safety and Tolerability: blood test results - total protein
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

Total protein in blood serum, g/L
35. Safety and Tolerability: blood test results - creatinine
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

Creatinine in blood serum, umol/L
36. Safety and Tolerability: blood test results - urea
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

Urea in blood serum, mmol/L
37. Safety and Tolerability: blood test results - glucose
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

Glucose in blood serum, mmol/L
38. Safety and Tolerability: blood test results - total bilirubin
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

Total bilirubin in blood serum, umol/L
39. Safety and Tolerability: blood test results - direct bilirubin
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

Direct bilirubin in blood serum, umol/L
40. Safety and Tolerability: blood test results - total cholesterol
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

Total cholesterol in blood serum, mmol/L
41. Safety and Tolerability: blood test results - triglycerides
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

Triglycerides in blood serum, mmol/L
42. Safety and Tolerability: blood test results - alanine transaminase (ALT)
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

ALT in blood serum, U/L
43. Safety and Tolerability: blood test results - aspartate transaminase (AST)
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

AST in blood serum, U/L
44. Safety and Tolerability: blood test results - alkaline phosphatase (ALP)
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

ALP in blood serum, U/L
45. Safety and Tolerability: 12-lead electrocardiogram (ECG) - heart rate
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: heart rate (beats per minute)
46. Safety and Tolerability: 12-lead electrocardiogram (ECG) - PQ interval
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: PQ interval (ms)
47. Safety and Tolerability: 12-lead electrocardiogram (ECG) - QRS complex
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: QRS complex (ms)
48. Safety and Tolerability: 12-lead electrocardiogram (ECG) - corrected QT interval (QTc)
[ Time Frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14) ]

12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: QTc (ms)
Open or close this module Eligibility
Minimum Age: 18 Years
Maximum Age: 45 Years
Sex: All
Gender Based:
Accepts Healthy Volunteers: Yes
Criteria:

Inclusion Criteria:

  1. Presence of written consent of the volunteer to participate in the study in accordance with applicable law.
  2. Healthy male and female caucasian volunteers aged 18 to 45 years (inclusive).
  3. Verified diagnosis "healthy": no deviations from the reference values of the data of standard clinical, laboratory and instrumental methods of examination.
  4. Systolic blood pressure (SBP) in the range of 110-130 mmHg; diastolic blood pressure (DBP) is 60-85 mmHg).
  5. 60-90 bpm at rest for heart rate (HR).
  6. 16-20 breaths/min for respiratory rate (RR).
  7. 35.5 to 36.9°C for body temperature.
  8. Body mass index (BMI) within the range of 18.5 ≤ BMI ≤ 30 kg/m2 with a body weight not less than 45 kg for female and not less than 55 kg for male volunteers.
  9. The consent of the volunteer (including the partner) to use adequate methods of contraception during the study and 30 days after its completion; for female volunteers - negative blood/urine test result for β-chorionic gonadotropin.
  10. Volunteers must behave adequately, coherent speech must be observed.

Exclusion Criteria:

  1. A history of allergy;
  2. A history of drug intolerance to the active and/or excipients in the study drugs;
  3. Chronic diseases of the kidneys, liver, gastrointestinal tract (GIT), cardiovascular, lymphatic, respiratory, nervous, endocrine, musculoskeletal, genitourinary and immune systems, as well as skin, blood and vision;
  4. History of gastrointestinal surgery (except appendectomy at least 1 year prior to screening);
  5. Diseases/conditions that in the opinion of the investigator may affect the absorption, distribution, metabolism or excretion of the study drugs (drugs);
  6. Acute infectious disease less than 4 weeks prior to screening;
  7. Taking medications that significantly affect hemodynamics and medications that affect liver function (barbiturates, omeprazole, cimetidine, etc.) less than 2 months prior to screening;
  8. Regularly taking a medicines less than 2 weeks before screening and taking a single medicine less than 7 days before screening;
  9. Donating blood or plasma less than 3 months before screening;
  10. Use of hormonal contraceptives (in women) less than 2 months before screening;
  11. The use of depot injections of any drug less than 3 months before screening;
  12. Pregnancy or lactation; positive blood/urine β-CGH test for women with preserved reproductive potential;
  13. Women of preserved reproductive potential with a history of unprotected intercourse within 30 days prior to study drug administration with an unsterilized partner;
  14. Participation in another clinical trial less than 3 months prior to screening or concurrently with the present study;
  15. Taking more than 10 units of alcohol (1 unit of alcohol is equivalent to 330 mL of beer, 150 mL of wine or 40 mL of spirits) in the week in the last month before inclusion in the study or anamnestic evidence of alcoholism, drug addiction, drug abuse;
  16. Smoking more than 10 cigarettes per day currently, or a history of smoking the specified number of cigarettes during the 6 months prior to screening; disagreement to abstain from smoking for the duration of the hospital stay;
  17. Positive blood tests for antibodies to human immunodeficiency virus (HIV) 1 and 2, antibodies to Treponema pallidum antigens, hepatitis B surface antigen (HBsAg), antibodies to hepatitis C virus antigens, rapid tests of biomaterial (nasopharyngeal and/or oropharyngeal swab) for Severe Acute Respiratory Syndrome Coronavirus 2 antigen (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19);
  18. Clinically significant abnormalities on the electrocardiogram (ECG);
  19. Positive urinalysis for narcotics and potent drugs;
  20. Positive test for the content of alcohol vapor in exhaled air.
  21. Scheduling an inpatient stay during the study period, for any reason other than hospitalization required by this protocol.
  22. Inability to meet the requirements of the protocol, perform the procedures prescribed in the protocol, follow the diet, activity regimen.
  23. Other conditions that, in the opinion of the Investigator, preclude inclusion of the volunteer in the study or may result in early withdrawal of the volunteer from the study, including fasting or a special diet (e.g. vegetarian, vegan, limited table salt) or a special lifestyle (night work, extreme physical activity).

Withdrawal criteria:

  1. A volunteer withdraws from further participation in the study;
  2. Failure of the volunteer to comply with the rules of participation in the study (skipping study procedures, independent use of drugs prohibited in the study, violation of dietary and lifestyle restrictions, etc.);
  3. Occurrence of causes/occurrence during the study of situations that threaten the safety of the volunteer (e.g., hypersensitivity reactions, etc.);
  4. Volunteers selected for the study in violation of the inclusion/inclusion criteria;
  5. Volunteer's development of severe adverse event during the study;
  6. Missing 2 or more consecutive blood samples or 3 or more blood samples during the same Study Period.
  7. Occurrence of vomiting/diarrhea within 6 hours of study drug administration;
  8. Positive urine test for narcotics and drugs;
  9. Positive breath alcohol vapor test.
  10. Positive pregnancy test in women;
  11. Positive test for COVID-19;
  12. The occurrence in the course of the study of other reasons that prevent the study according to the protocol.
Open or close this module Contacts/Locations
Locations: Russian Federation
Limited Liability Company "Research Center Eco-Safety"
[Recruiting]
Saint Petersburg, Russian Federation, 196143
Contact:Contact: Vasiliy Vasilyuk, MD, PhD +7 (901) 304 4248 vasilyuk_vb@ecosafety.ru
Open or close this module IPDSharing
Plan to Share IPD: Undecided
Open or close this module References
Citations:
Links:
Available IPD/Information:

Scroll up to access the controls Scroll to the Study top

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services